A few dozen groups representing patients, providers, and consumers are asking insurance commissioners across the U.S. to investigate the growing use of copay accumulators — a new weapon against widely used but controversial copay assistance that drug makers offer to consumers.
These have been embraced by a growing number of insurers and employers to keep down drug costs because accumulators do not count the value of any co-pay assistance cards or coupons toward out-of-pocket medicine costs that are applied toward deductibles.
About the Author Reprints
